Site icon pharmaceutical daily

U.S. Sucralfate Market to Surpass US$ 388.2 Million by 2026 – Coherent Market Insights

SEATTLE–(BUSINESS WIRE)–#DuodenalUlcers–According to Coherent Market Insights, the U.S. sucralfate market was valued at US$ 296.2 million in 2017, and is projected to exhibit a CAGR of 3.1% over the forecast period (2018–2026).

Key Trends and Analysis of the U.S. Sucralfate Market:

Key trends in market are increasing prevalence of gastrointestinal disorders and H. pylori-associated infections and increasing research and development activities by market players.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2975

Increasing number of people affected by H. pylori infection is expected to increase the risk of gastric and duodenal ulcers, which in turn is expected to augment growth of the U.S. sucralfate market. According to the data published by International Foundation for Gastrointestinal Disorders in 2017, the prevalence of gastroesophageal reflux disease in U.S. was around 18 to 28% of the total population. Similarly, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 2014, around 30 to 40% of people in the U.S. suffer from H. pylori infection, which increases the risk of duodenal and gastric ulcer development.

Ask for a Discount Now @ https://www.coherentmarketinsights.com/insight/request-discount/2975

Furthermore, increasing research and development activities is expected to drive the U.S. sucralfate market growth. For instance the University of Texas is conducting a clinical phase II study on sucralfate to improve oral intake in children with infectious oral ulcers. The study is expected to be completed by June 2019.

However, the availability of other over-the-counter products such as H2 antagonists, proton pump inhibitors, and antacids to reduce stomach acid for preventing heart burn and gastritis are major factors hindering the market growth. The alternative OTC/prescription medications include Tums (Calcium carbonate), Zantac 75 (ranitidine), Pepcid (Famotidine), Prevacid (lansoprazole), Prilosec (omeprazole), Protonix (pantoprazole), and Pepto-Bismol (bismuth subsalicylate).

Buy this report (Single Users License) @ https://www.coherentmarketinsights.com/insight/buy-now/2975

Key Market Takeaways:

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-sucralfate-market-2975

Report Segmentation:

Contacts

Mr. Raj Shah

Coherent Market Insights

1001 4th Ave.

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Exit mobile version